De-risk your immuno-oncology drug development with HUB Organoids®
Immunotherapy has shown substantial success in cancer treatment, however, its efficacy is limited to only a subset of patients. Treatment failure can be attributed to the lack of predictive biomarkers, a high degree of heterogeneity in patient tumors, immunosuppressive tumor features, and the lack of clinically relevant models for preclinical testing.
Download this Infosheet to discover:
- How HUB Organoids are superior preclinical models for immunotherapy drug development
- HUB’s service offerings for CAR-T or engineered T cells, and bispecifics antibodies testing
- Our Immuno-oncology biobanks including matched normal/tumor organoids and immune cells
- Our established immune cell and tumor organoid co-cultures